This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We previously reported clinical improvement, increase in putamen [18F]-dopa uptake on PET imaging, and neuropathologic evidence of sprouting of dopaminergic fibers following chronic intraputaminal delivery of glial cell line–derived neurotrophic factor (GDNF) in idiopathic Parkinson disease (PD).1–3 We now provide clinical and PET evidence of persistent efficacy lasting for at least 3 years following cessation of GDNF infusion in a patient with PD. This is a single-case observational study, providing Class IV evidence.
Footnotes
Supplemental data at www.neurology.org
Author contributions: N.K. Patel: research project: conception, organization, execution, including clinical assessments and analysis of clinical data; manuscript: writing of the first draft together with S. Javed. N. Pavese: research project: conception, execution including PET scanning and analysis; manuscript: review and critique of first draft, writing of the revised manuscript together with N.K. Patel and S. Javed. S. Javed: research project: conception, execution including clinical assessments; manuscript: writing of the first draft together with N.K. Patel. G.R. Hotton: research project: conception, execution including PET scanning; manuscript: review and critique of first draft. D.J. Brooks: research project: conception; manuscript: review and critique. S.S. Gill: research project: conception; manuscript: review and critique.
Study funding: No targeted funding reported.
Disclosure: N. Patel, N. Pavese, S. Javed, and G. Hotton report no disclosures. D. Brooks is employed part-time by GE Healthcare. S. Gill is a consultant to Renishaw plc and Medtronic Inc. Go to Neurology.org for full disclosures.
- Received August 20, 2012.
- Accepted in final form May 16, 2013.
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.